Global Hurler Syndrome Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Hurler Syndrome Market was valued at $680 mn. in 2025. During the forecast period 2025-2030, it is expected to grow at 8.5% CAGR, to an estimated market size of $1.0 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The Global Hurler Syndrome Market encompasses therapeutic interventions for Mucopolysaccharidosis Type I (MPS I), a rare autosomal recessive lysosomal storage disorder caused by a deficiency of the alpha-L-iduronidase enzyme. The scope includes Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplantation (HSCT), and emerging gene therapies, while excluding general supportive care and non-specific surgical interventions.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Hurler Syndrome Market in the period 2025-30:
- The market is undergoing a paradigm shift from chronic management toward disease-modifying gene therapies such as OTL-203 and RGX-111.
- Increased implementation of newborn screening and genetic testing is facilitating earlier diagnosis and timely therapeutic intervention.
- Research is intensifying into biologics capable of crossing the blood-brain barrier to address unmet needs in neurocognitive decline.
- Integration of Artificial Intelligence and machine learning is improving early biomarker classification and patient screening efficiency.
- Favorable orphan drug designations and government regulatory incentives are accelerating the clinical pipeline for rare metabolic disorders.
- Strategic collaborations between pharmaceutical giants and biotech startups are streamlining resource sharing for complex clinical trials.
- A growing focus on substrate reduction therapies (SRT) offers potential oral alternatives or complements to traditional intravenous treatments.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Enzyme Replacement Therapy (ERT)
- Hematopoietic Stem Cell Transplantation (HSCT)
- Gene & Emerging Therapies